Airway Epithelium Articles & Analysis
4 news found
Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced today it was awarded funding by the Cystic Fibrosis Foundation to pursue the development of the Feldan Shuttle technology as a pulmonary delivery agent for cystic fibrosis (CF). The award is part of the Cystic Fibrosis Foundation’s US$500 million ...
McCray and Feldan Therapeutics: The lungs, which evolved to be resistant to many outside stimuli, are widely recognized as difficult organs to deliver drugs into. The respiratory epithelium presents barriers due to its specialized cell types, secreted host defense factors and mucociliary transport. ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced that it is receiving advisory services and conditional funding from the National Research Council Industrial Research Assistance Program (NRC IRAP), to support the development of Orion’s lead compound, OB-002, a promising treatment for ...
In an article published in Nature Communications, entitled "Engineered Amphiphilic Peptides Enable Delivery of Proteins and CRISPR Associated Nucleases to Airway Epithelia” Dr. David Guay, Research Director of Feldan Therapeutics, and collaborator Dr. Paul McCray, from the University of Iowa Carver College of Medicine, demonstrate that Feldan’s engineered amphiphilic peptides (Feldan ...